Evidence map›Paper›PMID 40996066›Full record

ArticleEpidemiology (Cambridge, Mass.)2025

Illustrating an Adaptive Prespecification Framework for Observational Research: Target Trial Emulations Comparing Immunomodulator Treatments for COVID-19.

Andrew R Weckstein, Vera Frajzyngier, Sarah E Vititoe, Aidan Baglivo, Elisha Beebe, Priya Govil, Marie C Bradley, Silvia Perez-Vilar, Wei Liu, Donna R Rivera and 4 more

Abstract read
In one paragraph

Article in Epidemiology (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andrew R WecksteinFrom the Aetion, Inc., New York City, NY.ORCID 0000-0002-6227-6796
Vera FrajzyngierFrom the Aetion, Inc., New York City, NY.ORCID 0009-0004-5141-1501
Sarah E VititoeFrom the Aetion, Inc., New York City, NY.
Aidan BaglivoFrom the Aetion, Inc., New York City, NY.
Elisha BeebeFrom the Aetion, Inc., New York City, NY.
Priya GovilFrom the Aetion, Inc., New York City, NY.
Marie C BradleyOffice of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD.
Silvia Perez-VilarOffice of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, MD.
Wei LiuOffice of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. FDA, Silver Spring, MD.
Donna R RiveraOncology Center of Excellence, U.S. FDA, Silver Spring, MD.
Tamar LaskyOffice of the Commissioner, U.S. FDA, Silver Spring, MD.
Aloka ChakravartyOffice of the Commissioner, U.S. FDA, Silver Spring, MD.
Elizabeth M GarryFrom the Aetion, Inc., New York City, NY.
Nicolle M GattoFrom the Aetion, Inc., New York City, NY.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rigid prespecification can be impractical for noninterventional studies using secondary datasets, where data-driven flexibility is often required. Using target trial emulations comparing immunomodulator treatments for COVID-19, we piloted an adaptive strategy that accommodates warranted mid-course refinements within a prespecified framework. Our preregistered protocol outlined an initial study plan along with predetermined diagnostic thresholds and contingencies. Implementation proceeded through sequential phases, allowing researcher decisions to be guided by prespecified criteria under varying degrees of blinding to results. The adaptive approach led to alterations in the underlying target trial and to the analysis plan used for emulation, strengthening the plausibility of causal assumptions and improving the relevance of findings. During the initial baseline phase, indicated contingencies included sample restrictions, redefining treatments from class-level to product-specific comparisons, a revised propensity score model, and weight truncation. In the subsequent postbaseline phase, diagnostic checks triggered a modified causal contrast, inverse probability of censor weighting to address noncompliance, cause-specific hazard estimation to contextualize competing events, and additional reporting of hazard ratios for progressively truncated follow-up periods. For a secondary study objective, the adaptive framework allowed for some iterative attempts to improve validity while providing a clear stopping point. Similar approaches could lend transparent structure to the process of learning what causal questions the data are equipped to support. Beyond guarding against researcher bias, prespecification of adaptive protocols may promote more robust designs by encouraging investigators to be explicit about their assumptions, strategies for interrogating those assumptions, and specific criteria for determining when and how deviations may be required.

Indexed as

COVID-19 Drug TreatmentImmunomodulating AgentsObservational Studies as TopicCOVID-19HumansPropensity ScoreResearch DesignSARS-CoV-2Immunomodulating AgentsCOVID-19Epidemiologic research designPharmacoepidemiologyReal world evidenceReproducibility of resultsResearch design/standardsTarget trial emulationTreatment outcome

Identifiers

PMID40996066
PMCPMC12459141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.